STI571 in Treating Patients With Recurrent Leukemia
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Imatinib mesylate may interfere with the growth of cancer cells and may be an
effective treatment for leukemia.
PURPOSE: Phase I trial to study the effectiveness of imatinib mesylate in treating patients
who have recurrent leukemia.